Natalia Harvey
Medical · Coral Springs, FLNPI 1497156160
Payments from drug & device makers
Across 145 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$510
- Novo Nordisk$477
- GSK$222
- Philips North America LLC$216
- Boehringer Ingelheim$191
- Amgen$173
- plus $973 from 21 others
What the payments were for
- Food & beverage$2,762100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 38 | $510 |
| Novo Nordisk | 25 | $477 |
| GSK | 11 | $222 |
| Philips North America LLC | 5 | $216 |
| Boehringer Ingelheim | 7 | $191 |
| Amgen | 10 | $173 |
| Johnson & Johnson | 5 | $107 |
| Pfizer | 5 | $102 |
| Amarin Pharma, Inc. | 5 | $90 |
| Bayer | 3 | $80 |
| Novartis | 5 | $77 |
| Cvrx, Inc. | 4 | $74 |
| Exact Sciences | 2 | $58 |
| E.r. Squibb & Sons, L.L.C. | 3 | $57 |
| AstraZeneca | 3 | $50 |
| Sanofi-aventis U.S. LLC | 1 | $38 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Edwards Lifesciences | 1 | $19 |
| Vivus LLC | 1 | $19 |
| Astellas Pharma US Inc | 1 | $18 |
| AbbVie | 1 | $16 |
| Baxter Healthcare | 1 | $15 |
| Boston Scientific | 1 | $15 |
How this compares
$2,762 in reported general payments places this provider in the 75th percentile of 2,031 medical providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 44 | $71,153 |
| OzempicSemaglutide | 43 | $61,512 |
| XareltoRivaroxaban | 31 | $35,169 |
| RybelsusSemaglutide | 13 | $26,127 |
| EliquisApixaban | 16 | $23,827 |
| Repatha SureclickEvolocumab | 19 | $11,616 |
| Rosuvastatin Calcium | 140 | $1,074 |
| Atorvastatin Calcium | 85 | $683 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 73 | $610 |
| Amlodipine Besylate | 93 | $540 |
| Levothyroxine Sodium | 48 | $533 |
| Glipizide ErGlipizide | 26 | $531 |
| Metoprolol Succinate | 46 | $501 |
| Losartan Potassium | 40 | $445 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $477 | $87,63956 claims |
| Boehringer IngelheimJardiance | $191 | $71,15344 claims |
| Johnson & JohnsonXarelto | $107 | $35,16931 claims |
| PfizerEliquis | $102 | $23,82716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,031 medical providers in Florida.
Other medical in Coral Springs
- Gary RubinRockledge$2.1M
- Shanna MirantiNaples$415K
- Krystie LennoxBoca Raton$245K
- Jihan RamadanWellington$238K
- Ilanit SamuelsMiami$211K
- Erin DouceyWinter Haven$202K
- Kathleen TrummerWellington$166K
- Sandra SnyderTampa$156K
- Francine PhillipsLand O Lakes$145K
- Chelsie FerrellDeland$132K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.